R. Gordo

Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program

P. Garrido, R. García-Campelo, D. Rodríguez-Abreu, 2022, Oncotarget.

Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib

B. Massuti, M. Lázaro, I. Oyagüez, 2020, Lung cancer management.

Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer

J. Trigo, D. Aguiar-Bujanda, J. Oramas, 2019, AntiCancer Research.

Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer

D. Isla, S. Grau, D. Rubio-Rodríguez, 2016, ClinicoEconomics and outcomes research : CEOR.

Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain

F. Rojo, M. Majem, A. Ortega, 2022, Global & regional health technology assessment.